Related Experiment Video
Updated: Jun 2, 2026
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
Published on: April 3, 2026
Virtual screening and further development of novel ALK inhibitors
Masako Okamoto1, Hirotatsu Kojima, Nae Saito
1Drug Discovery Department, Research & Development Division, PharmaDesign, Inc., Hatchobori, Chuo-ku, Tokyo, Japan. okamoto@pharmadesign.co.jp
Abstract:
Anaplastic lymphoma kinase (ALK) has been in the spotlight in recent years as a promising new target for therapy of non-small-cell lung cancer (NSCLC). Since the identification of the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene in some NSCLC patients was reported in 2007, various research groups have been seeking ALK inhibitors. Above all, crizotinib (PF-02341066) has been under clinical trial, and its therapeutic efficacy of inhibiting ALK in NSCLC has been reported. Among anticancer drugs, drug resistance appears frequently necessitating various kinds of inhibitors. We identified novel ALK inhibitors by virtual screening from the public chemical library collected by the Chemical Biology Research Initiative (CBRI) at the University of Tokyo, and inhibitors that are more potent were developed.
Insights
Researchers identified novel Anaplastic Lymphoma Kinase (ALK) inhibitors for non-small-cell lung cancer (NSCLC) therapy. Virtual screening of a chemical library yielded potent new compounds to combat drug resistance.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Anaplastic Lymphoma Kinase (ALK) is a key therapeutic target in non-small-cell lung cancer (NSCLC).
- The EML4-ALK fusion gene, identified in 2007, drives NSCLC in a subset of patients.
- Drug resistance to existing ALK inhibitors necessitates the development of novel therapeutic agents.
Purpose of the Study:
- To identify novel Anaplastic Lymphoma Kinase (ALK) inhibitors.
- To develop more potent inhibitors to overcome drug resistance in non-small-cell lung cancer (NSCLC).
Main Methods:
- Virtual screening of a public chemical library from the Chemical Biology Research Initiative (CBRI).
- Identification and development of novel ALK inhibitors.
Main Results:
- Novel ALK inhibitors were successfully identified through virtual screening.
- The developed inhibitors demonstrated increased potency compared to existing agents.
Conclusions:
- The identified compounds represent promising candidates for novel non-small-cell lung cancer (NSCLC) therapies.
- These findings contribute to the ongoing effort to develop effective ALK inhibitors for cancer treatment.
